LYPD6B Antibody (Center) (Ascites)
Mouse Monoclonal Antibody (Mab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND

Application
| WB, E |
|---|---|
| Primary Accession | Q8NI32 |
| Other Accession | Q9D7F2, NP_808879.2 |
| Reactivity | Human, Mouse |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG2b |
| Clone/Animal Names | 634CT7.10.1 |
| Calculated MW | 20656 Da |
| Antigen Region | 79-108 aa |
| Gene ID | 130576 |
|---|---|
| Other Names | Ly6/PLAUR domain-containing protein 6B, LYPD6B |
| Target/Specificity | This LYPD6B antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 79-108 amino acids from the Central region of human LYPD6B. |
| Dilution | WB~~1:500~4000 E~~Use at an assay dependent concentration. |
| Format | Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | LYPD6B Antibody (Center) (Ascites) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | LYPD6B |
|---|---|
| Function | Likely acts as a modulator of nicotinic acetylcholine receptors (nAChRs) activity (PubMed:26586467, PubMed:34631692). In vitro acts on nAChRs in a subtype- and stoichiometry-dependent manner (PubMed:26586467). Modulates specifically alpha-3(3):beta-4(2) nAChRs by enhancing the sensitivity to ACh, decreasing ACh-induced maximal current response and increasing the rate of desensitization to ACh; has no effect on alpha-7 homomeric nAChRs; modulates alpha-3(2):alpha- 5:beta-4(2) nAChRs in the context of CHRNA5/alpha-5 variant Asn-398 but not its wild-type sequence (PubMed:26586467). However, according to another report in vitro it can weakly inhibits alpha-7 nAChRs (PubMed:34631692). |
| Cellular Location | Cell membrane; Lipid-anchor, GPI- anchor |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The function of this protein is unknown.
References
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :
Ni, J., et al. Mol. Biol. Rep. 36(4):697-703(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.


